Erythropoietin (Epoetin alfa)

Generic name
Erythropoietin (Epoetin alfa)
Brand name
ATC Code
B03XA01
Compare …

Erythropoietin (Epoetin alfa)

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

A half-life of about 6.2 to 8.7 hours has been reported in children with chronic renal impairment after intravenous administration of multiple doses of epoetin alfa. The pharmacokinetic profile of epoetin alfa in children and adolescents is that same as that of adults.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Anaemia due to chronic renal insufficiency with haemodialysis
  • Intravenous
    • ≥ 1 year
      [1] [2] [3]
      • Initially: 50 IU/kg/dose 3x per week. Maintenance dose: Increase or decrease the dose in 25 IU/kg increments until the desired hemoglobin concentration is achieved (between 11 g/dl and 12 g/dl)..

      • Children with a bodyweight of under 30 kg usually need a higher maintenance dose than children above 30 kg and adults.

Renal impaiment in children > 3 months

GFR ≥10 ml/min/1.73m2: Dose adjustment not required.

GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

OTHER ANTIANEMIC PREPARATIONS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Other antianemic preparations
B03XA02
B03XA01

References

  1. Medice Arzneimittel Pu?tter GmbH & Co KG, SmPC Abseamed (EU/1/07/412/001-055) 28-09-2015, www.geneesmiddeleninformatiebank.nl
  2. Janssen-Cilag B.V., SmPC Eprex (RVG 18479) 25-04-2016, www.geneesmiddeleninformatiebank.nl
  3. Kidney Disease: Improving Global Outcomes (KDIGO), Clinical practice guidelines: Anemia in CKD, 2012, 2 (4)

Changes

Therapeutic Drug Monitoring


Overdose